Zevra Therapeutics Inc. (ZVRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $540.30M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zevra Therapeutics Inc. (ZVRA) P/E Ratio & Valuation History
Zevra Therapeutics (ZVRA) trades at 11.6x trailing earnings and 3.7x sales. Its P/S of 3.7x is below its 5-year median of 9.2x. Its forward P/E is 9.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 18.4% higher over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 11.6x |
| Forward P/E | 9.8x |
| Price to sales | 3.7x |
| Price to book | 2.3x |
| EV/EBITDA | 5.0x |
| Price to FCF | 14.4x |
| EV/FCF | 11.2x |
| PEG | N/A |
| FCF yield | 7.0% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.7x | 9.2x | N/A |
| P/B | 2.3x | 3.0x | N/A |
Valuation History
Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 0.9x in 2019 to 17.0x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $8.96 | 149.3x | 4.7x | 3.3x |
| 2024 | $8.34 | N/A | 17.0x | 11.3x |
| 2023 | $6.55 | N/A | 8.9x | 4.4x |
| 2022 | $4.59 | N/A | 15.6x | 2.1x |
| 2021 | $8.71 | N/A | 7.4x | 2.4x |
| 2020 | $11.20 | N/A | 3.3x | N/A |
| 2019 | $6.06 | N/A | 0.9x | N/A |
| 2018 | $28.48 | N/A | N/A | N/A |
| 2017 | $64.80 | N/A | N/A | N/A |
| 2016 | $47.20 | N/A | N/A | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ZVRA
What is ZVRA's forward P/E ratio?
Zevra Therapeutics has a forward P/E ratio of 9.8x.
Is ZVRA stock overvalued?
GNG's valuation label for ZVRA is Undervalued.
What is ZVRA's price to sales ratio?
Zevra Therapeutics has a price to sales ratio of 3.7x.
ZVRA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors